Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
47 stopped studies mapped to Invasive Breast Carcinoma and descendants · 100% state a reason
Over the 47 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast… | Phase 2 / Phase 3 | suspended | Mar 13, 2017 | M.D. Anderson Cancer Center | PI Requested | Other (stated, no rule matched) |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer… | Early Phase 1 | terminated | Jan 8, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Phase 4 | terminated | Jan 11, 2022 | University of Washington | Study ended earlier than anticipated due to end of funding. | Funding |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | Phase 1 / Phase 2 | withdrawn | Aug 5, 2016 | Eli Avisar, MD | Lack of Funding | Funding |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT05447910 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative… | — | terminated | Jul 7, 2022 | Mayo Clinic | insufficient funding | Funding |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2021 | M.D. Anderson Cancer Center | Termination was requested by study supporter IKENA oncology | Other (stated, no rule matched) |
| NCT04252859 | [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma | Phase 2 | terminated | Feb 5, 2020 | University of Utah | PI is leaving the institution. | Other (stated, no rule matched) |
| NCT01938833 | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2013 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by Sponsor | Other (stated, no rule matched) |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the… | Phase 2 | withdrawn | Jan 5, 2022 | M.D. Anderson Cancer Center | 0 participants recruited | Enrollment / accrual |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who… | Phase 2 | terminated | Mar 13, 2019 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients… | Phase 3 | suspended | Jan 16, 2014 | Academic and Community Cancer Research United | Total enrollment number is being lowered | Enrollment / accrual |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Phase 1 | terminated | Aug 24, 2016 | National Cancer Institute (NCI) | Inadequate Accrual Rate | Enrollment / accrual |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma… | N/A | terminated | Jun 3, 2019 | Alpha Tau Medical LTD. | Difficulty in recruiting patients | Enrollment / accrual |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT04901299 | Fulvestrant + Neratinib In Breast Cancer(HER2-Signal) | Phase 2 | withdrawn | May 25, 2021 | Massachusetts General Hospital | Team decision | Other (stated, no rule matched) |
| NCT04088435 | Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer | — | terminated | Sep 12, 2019 | University of Louisville | Low accrual | Enrollment / accrual |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor… | Phase 1 | terminated | Apr 25, 2017 | Jonsson Comprehensive Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | N/A | withdrawn | Apr 16, 2020 | Xoft, Inc. | Lack of site participation | Other (stated, no rule matched) |
| NCT03630653 | Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse(FIGARO) | N/A | terminated | Aug 15, 2018 | Institut Cancerologie de l'Ouest | The study was stopped prematurely due to insufficient recruitment | Enrollment / accrual |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for… | Phase 2 | terminated | May 13, 2014 | Dana-Farber Cancer Institute | no enough patients | Other (stated, no rule matched) |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | Phase 2 | terminated | Sep 4, 2013 | Ronald Weigel | Drugs unavailable | Other (stated, no rule matched) |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in… | N/A | terminated | Dec 24, 2012 | M.D. Anderson Cancer Center | due to lack of funding | Funding |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | N/A | withdrawn | Feb 19, 2018 | Jaroslaw Hepel | Secondary to medicare coverage determination | Other (stated, no rule matched) |
| NCT04549584 | Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast…(NEO-SMART) | — | terminated | Sep 16, 2020 | Seoul National University Hospital | due to poor enrolled patients | Enrollment / accrual |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative… | Phase 2 | terminated | Sep 8, 2016 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01409811 | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated… | N/A | terminated | Aug 4, 2011 | City of Hope Medical Center | Study closed after it became too difficult to interest patients in participating. | Other (stated, no rule matched) |
| NCT03523299 | Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer | N/A | withdrawn | May 14, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal investigator wishes to revisit design and start a new study | Investigator |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | Early Phase 1 | terminated | Jun 7, 2010 | University of California, San Diego | Inadequate subject accrual | Enrollment / accrual |
| NCT03238703 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | Phase 4 | withdrawn | Aug 3, 2017 | Fred Hutchinson Cancer Center | Administrative closure based on sponsor recommendation, prior to subject enrollment | Enrollment / accrual |
| NCT02365714 | CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)(CK-SAPBI) | Phase 1 / Phase 2 | terminated | Feb 19, 2015 | Georgetown University | Slow accrual | Enrollment / accrual |
| NCT01754519 | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer… | Phase 2 | terminated | Dec 21, 2012 | Roswell Park Cancer Institute | IDE not submitted | Other (stated, no rule matched) |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | Phase 2 | terminated | Sep 8, 2005 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01791998 | Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating… | N/A | withdrawn | Feb 15, 2013 | University of Chicago | Funding was time sensitive and expired. No subjects enrolled. | Enrollment / accrual |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | Phase 2 | terminated | Sep 3, 2010 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Difficulty meeting patient accrual goals | Enrollment / accrual |
| NCT00016276 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and… | Phase 3 | terminated | Sep 4, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01100489 | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or… | Phase 2 | withdrawn | Apr 9, 2010 | Case Comprehensive Cancer Center | No accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials